FDA Approves Mirdametinib for Adult and Paediatric Patients with NF1 Who Have Symptomatic Plexiform Neurofibromas Not Amenable to Complete Resection By Ogkologos - March 20, 2025 831 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ReNeu study Source RELATED ARTICLESMORE FROM AUTHOR Ovarian Reserve Better Indicator of Adjuvant Chemotherapy Benefit than Self-Reported Menopause Status, Age, or Other Hormone Levels Immune-Modulating SBRT Plus Anti-PD-L1 May Convert Immune-Cold ER-positive, HER2-negative EBC Into More Inflamed Tumours and Improve Response EMA Recommends Extension of Therapeutic Indications for Serplulimab MOST POPULAR For Early-Stage Lung Cancer, Study Identifies Potential New Biomarker, Treatment Target January 3, 2019 Νέος βιοδείκτης για τις γυναίκες πριν την εμμηνόπαυση August 1, 2019 FDA Approves Tremelimumab in Combination with Durvalumab and Platinum-Based Chemotherapy for... November 15, 2022 Trialling a new way to boost CAR T-cell therapy June 23, 2021 Load more HOT NEWS Perioperative Chemotherapy with FLOT Improves Survival Among Patients with Resectable Oesophageal... Trastuzumab Deruxtecan in Second-Line Treatment for Patients with HER2-positive Advanced Gastric... Coronavírus e COVID-19: o que as pessoas com câncer precisam saber Vorasidenib Treatment Shows Promise for Some Low-Grade Gliomas
